Trial Profile
A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CheckMate 374
- Sponsors Bristol-Myers Squibb
- 14 Apr 2022 Status changed from active, no longer recruiting to completed.
- 16 Feb 2019 Updated safety and efficacy results (n=44) presented at the 2019 Genitourinary Cancers Symposium
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.